Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis case report

We examined pharmacokinetics of paclitaxel and carboplatin in a FIGO Stage IIIb ovarian cancer patient with hemodialysis-dependent chronic renal failure. The patient suffered from recurrence of the disease after treatment with optimal debulking surgery and postoperative chemotherapy consisting of cisplatin, epirubicin and cyclophosphamide, and she was treated with combined paclitaxel and carboplatin as second-line chemotherapy. The carboplatin dose was chosen to produce a target area under the concentration/time curve (AUC) of 5.0 microg-min/ml according to a published formula. Four-hour hemodialysis was started 24 hours and 16 hours after the end of carboplatin administration in the first and second courses of the chemotherapy, respectively. Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis. However, an attenuation pattern of paclitaxel was almost similar between the first and the second courses, indicating that the change in blood concentration of paclitaxel was similar to that of patients with normal renal function. Hematological and nonhematological adverse effects were at an acceptable degree. The evidence suggests that even patients with chronic renal failure can undergo combination chemotherapy of paclitaxel and carboplatin without suffering any severe adverse effects by determining the time to start hemodialysis.

Pharmacokinetics; Paclitaxel; Carboplatin; Hemodialysis; Ovarian cancer

[1] Tokunaga J.，Kikukawa H., Nishi K., Kitani K., Fujii J., Honda J. et al.: "Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic MVAC chemotherapy (in Japanese)". Jpn. J. Cancer Chemother., 2000, 27, 2079.

[2] LeRoy A.F., Wehling M.L., Sponseller H.L., FriaufW.S., Solomon R.E., Dedrick R.L. et al.: "Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry". Biochem". Med., 1977, 18, 184.

[3] Longnecker S.M., Donehower R.C., Cates A.E., Chen T.L., Brundrett R.B., Grochow L.B. et al.: "High-performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial". Cancer Treat. Rep., 1987, 71, 53.

[4] Wright J.G., Boddy A.V., Highley M., Fenwick J., McGill A., Calvert A.H.: "Estimation of glomerular filtration rate in cancer patients". Br. J. Cancer, 2001, 84, 452.

[5] Chatelut E., Rostaing L., Gualano V., Vissac T., De Forni M., TonThat H. et al.: "Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysisdependent renal insufficiency". Nephron, 1994, 66, 157.

[6] Watanabe M., Aoki Y., Tomita M., Sato T., Takaki Y., Kato N. et al.: "Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer". Gynecol. Oncol., 2002, 84, 335.

[7] Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E. et al.: "Carboplatin dosage: prospective evaluationof a simple formula based on renal function". J. Clin. Oncol., 1989, 7, 1748.

[8] Koeller J.M., Trump D.L., Tutsch K.D., Earhart R.H., Davis T.E., Tormey D.C.: "Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion". Cancer, 1986, 15, 222.

[9] Kurata H., Yoshiya N., Igarashi H., Kaneko T., Kodama S., Tanaka K. et al.: "Pharmacokinetics of carboplatin in a patient under hemodialysis (in Japanese)". Jpn. J. Cancer Chemother., 1994, 21, 547.

[10] Takano K., Shimosato C., Ogino Y., Hosoda S., Iwasaku K.: "Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with ovarian cancer (in Japanese)". Adv. Obstet. Gynecol., 2003, 55, 400.

[11] Bokemeyer C., Hartmann J.T., Kuczyk M.A., Truss M.C., Beyer J., Jonas U. et al.: "The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors". World J. Urol., 1996, 14, 354.

[12] Horikoshi N., Inoue K., Aiba K., Mukaiyama T., Ogihara A., Sumida T. et al.: "Phase I study of paclitaxel (in Japanese)". Jpn. J. Cancer Chemother., 1994, 21, 2407.

[13] Dreicer R., Gustin D.M., See W.A., Williams R.D.: "Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy". J. Urol., 1996, 156, 1606.

[14] Woo M.H., Gregornik D., Shearer P.O., Meyer W.H., Relhng M.V.: "Pharmacokinetics of paclitaxel in an anephric patient". Cancer Chemother. Pharmacol., 1999, 43, 92.

[15] Tamura T., Sasaki Y., Nishiwaki Y., Saijo N.: "Phase I study of paclitaxel by three-hour infusion; hypotension just after infusion is one of the major dose-limiting toxicities". Jpn. J. Cancer Res., 1995, 86, 1203.